conmed corporation is a global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services that allow our physician customers to deliver high quality care and as a result, enhanced clinical outcomes for their patients. our products are technological leaders in the specialties that we serve: orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. conmed's mission, and the focus of every employee around the world, is to improve the quality of health care by designing, producing and marketing innovative, high-quality products. our emphasis is on our customer’s satisfaction and on our enhanced patient outcomes. we strive to demonstrate thoughtful leadership, provide meaningful opportunities for employees, and be a responsible member of the local communities in which we conduct business. conmed is headquartered in beautiful, upstate new york (utica), and employs approximately 3500
Company profile
Ticker
CNMD
Exchange
Website
CEO
Curt Hartman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical • Fonar ...
SEC CIK
Corporate docs
Subsidiaries
Aspen Laboratories, Inc. • Biorez, Inc. • Biorez Pty Ltd • Buffalo Filter LLC • CONMED Andover Medical, Inc. • CONMED Austria GmbH • CONMED Denmark ApS • CONMED Deutschland GmbH • CONMED Endoscopic Technologies, Inc. • CONMED France SAS ...
IRS number
160977505
CNMD stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEFA14A
Additional proxy soliciting materials
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Other Events
27 Feb 24
8-K
CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
31 Jan 24
8-K
Other Events
5 Dec 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
CONMED Corporation Announces Third Quarter 2023 Financial Results
25 Oct 23
8-K
Other Events
10 Aug 23
Transcripts
CNMD
Earnings call transcript
2023 Q4
31 Jan 24
CNMD
Earnings call transcript
2023 Q3
25 Oct 23
CNMD
Earnings call transcript
2023 Q2
26 Jul 23
CNMD
Earnings call transcript
2023 Q1
27 Apr 23
CNMD
Earnings call transcript
2022 Q4
2 Feb 23
CNMD
Earnings call transcript
2022 Q3
27 Oct 22
CNMD
Earnings call transcript
2022 Q2
28 Jul 22
CNMD
Earnings call transcript
2022 Q1
8 May 22
CNMD
Earnings call transcript
2021 Q4
27 Jan 22
CNMD
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.50 mm | 30.50 mm | 30.50 mm | 30.50 mm | 30.50 mm | 30.50 mm |
Cash burn (monthly) | (no burn) | 237.67 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 1.62 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 28.88 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 121.5 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 273 |
Opened positions | 54 |
Closed positions | 42 |
Increased positions | 95 |
Reduced positions | 88 |
13F shares | Current |
---|---|
Total value | 3.54 tn |
Total shares | 35.28 mm |
Total puts | 164.50 k |
Total calls | 177.50 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.95 mm | $499.11 bn |
Vanguard | 3.44 mm | $346.97 bn |
Capital Research Global Investors | 2.47 mm | $248.81 bn |
Earnest Partners | 2.27 mm | $228.43 bn |
STT State Street | 1.18 mm | $119.11 bn |
BAC Bank Of America | 1.06 mm | $106.97 bn |
AMP Ameriprise Financial | 967.17 k | $97.54 bn |
Champlain Investment Partners | 943.26 k | $95.13 bn |
Loomis Sayles & Co L P | 789.14 k | $79.64 bn |
MCQEF Macquarie | 743.61 k | $74.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Heather L Cohen | Common Stock | Grant | Acquire A | No | No | 76.08 | 227 | 17.27 k | 35,992 |
28 Mar 24 | Todd W. Garner | Common Stock | Grant | Acquire A | No | No | 76.08 | 227 | 17.27 k | 227 |
8 Mar 24 | Heather L Cohen | Common Stock | Payment of exercise | Dispose F | No | No | 85.225 | 23,847 | 2.03 mm | 35,765 |
8 Mar 24 | Heather L Cohen | Common Stock | Option exercise | Acquire M | No | No | 78.76 | 25,000 | 1.97 mm | 59,612 |
8 Mar 24 | Heather L Cohen | Common Stock | Payment of exercise | Dispose F | No | No | 85.425 | 22,258 | 1.90 mm | 34,612 |
8 Mar 24 | Heather L Cohen | Common Stock | Option exercise | Acquire M | No | No | 59.96 | 27,500 | 1.65 mm | 56,870 |
8 Mar 24 | Heather L Cohen | Options To Purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 78.76 | 25,000 | 1.97 mm | 0 |
8 Mar 24 | Heather L Cohen | Options To Purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 59.96 | 27,500 | 1.65 mm | 0 |
7 Mar 24 | Brent Lalomia | Common Stock | Payment of exercise | Dispose F | No | No | 85 | 26 | 2.21 k | 957.057 |
7 Mar 24 | Brent Lalomia | Common Stock | Option exercise | Acquire M | No | No | 0 | 75 | 0.00 | 983.057 |
News
Cracking The Code: Understanding Analyst Reviews For Conmed
1 Feb 24
Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $100-Report Released on 31 January 2024
1 Feb 24
JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $115
1 Feb 24
These Analysts Revise Their Forecasts On CONMED After Q4 Results
1 Feb 24
Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $98
1 Feb 24